This summary covers key developments in health news, including Mitsubishi Pharma's bidding war, legal actions involving J&J ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a survey on nicotine use in ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

In the U.S., Medicare Advantage plans must now cover Biogen's ALS drug Qalsody, as directed by the Centers for Medicare & ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

CMS has reportedly directed Medicare Advantage plan providers to cover Biogen's drug Qalsody for ALS following reports it was ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Interest in NfL as a biomarker of response has ramped up since it was used as a surrogate endpoint to support the accelerated approval of Biogen's Qalsody (tofersen), an antisense oligonucleotide ...